arrow
S

Sundar Jagannath

Icahn School of Medicine at Mount Sinai
H指数:109
被引数:6.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy

与BCMA car-t细胞治疗相关的小肠结肠炎中粘膜car-t细胞的持久性和炎症重塑

2026-09-230
PRE
Timing and Pattern of Extraosseous Dissemination Are Key Determinants of Survival in Multiple Myeloma

骨外播散的时机和模式是影响多发性骨髓瘤预后的关键因素

2026-05-140
PRE
Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myeloma

基线绝对淋巴细胞计数、C反应蛋白和铁蛋白可预测多发性骨髓瘤中CAR T细胞相关毒性和结局。

2026-03-300
PRE
Healthcare resource utilization and costs in patients with multiple myeloma who received 1 to 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, and were exposed to and discontinued lenalidomide in the United States

美国接受1至3线前期治疗(包括蛋白酶体抑制剂和免疫调节药物)并曾使用后停用来那度胺的多发性骨髓瘤患者的医疗资源利用和费用

2025-11-190
OAAI
Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses

在LINKER-MM1研究中,复发/难治性多发性骨髓瘤患者的linvoseltamab治疗:更长时间的随访和亚组分析

2025-11-120
OAAI
Long-term Remission After Cilta-Cel in Multiple Myeloma Is Linked to Diverse T Cells and Low Myeloid Suppression

Cilta-Cel治疗多发性骨髓瘤后的长期缓解与多样化的T细胞和较低的髓系抑制相关

2025-11-070
OAAI
Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma

髓外疾病而非骨旁疾病预示着CAR T细胞疗法在多发性骨髓瘤中的不良结局。

2025-05-030
PRE
Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review

对复发/难治性多发性骨髓瘤预后因素重要性的排序:基于系统文献综述的国际医师专家组共识

2025-04-030
OAAI
Elotuzumab-Iberdomide-Dexamethasone Combination Therapy Activates T and NK Cells within the Immune Microenvironment of Multiple Myeloma Patients

Elotuzumab-Iberdomide-Dexamethasone联合疗法可激活多发性骨髓瘤患者免疫微环境中的T细胞和NK细胞

BLOOD
IF23.1
2024-11-050
PRE
A Phase 2 Study of Daratumumab in Combination with Dose-Attenuated Bortezomib, Lenalidomide, and Dexamethasone in Transplant Ineligible Older Adults with Newly Diagnosed Multiple Myeloma

一项关于达鲁珠单抗联合减量硼替佐米、来那度胺和地塞米松在移植不适宜的老年新诊断多发性骨髓瘤患者中的2期研究

BLOOD
IF23.1
2024-11-050
PRE
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
2024-09-162
OAAI
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

多发性骨髓瘤的综合分子谱分析可确定精细的拷贝数和表达亚型

2024-08-192
OAAI
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma
2024-07-241
OAAI